Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates

Financial Performance - Idexx Laboratories reported quarterly earnings of $2.62 per share, exceeding the Zacks Consensus Estimate of $2.40 per share, and up from $2.32 per share a year ago, representing an earnings surprise of 9.17% [1] - The company posted revenues of $954.29 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.87%, compared to year-ago revenues of $901.6 million [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $3.02 on revenues of $1.02 billion, and for the current fiscal year, it is $11.95 on revenues of $4.16 billion [7] - The estimate revisions trend for Idexx is currently unfavorable, leading to a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Idexx belongs, is currently in the top 34% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - Teleflex, another company in the same industry, is expected to report quarterly earnings of $3.86 per share, reflecting a year-over-year change of +14.2% [9]